Kornimate/medical-research-clean huggingface dataset:
interest of fluorescein in fluorescence-guided resection of gliomas (flegme)

Conditions: Glioblastoma, Adult

Summary: fluorescence guidance is a safe and efficient tool for glioblastomas resection. the most widely used technique is based on 5-aminolevulinic acid (5ala), which stains glioblastoma cells through a metabolic abnormality and thus helps in defining tumoral edges through a modified microscope. a multicentric, randomized study comparing 5ala guided surgery with conventional procedures showed that this technique doubles the rate of complete removal on post-operative magnetic resonance imaging (mri), and increases the 6 months progression-free survival. more recently, fluorescein appeared as an interesting alternative fluorophore for glioblastomas, with a highly reduced cost (2.5 euros versus 1000 euros per dose). however its use remains scarcely studied and its clinical benefit unsure. in that context, the investigators propose a randomized trial comparing conventional " white light " surgery with fluorescein-guided resection of glioblastomas, in order to assess the relevance of this technique in glioblastomas removal.


Eligibility criteria:
inclusion criteria: * age between 18 and 79 * karnofsky index \> 70 % * brain mri showing a parenchymal lesion with typical features of glioblastoma, \< 1week * achievable gross total removal, as assessed by the neurosurgical staff * written consent exclusion criteria: * contraindication to fluorescein * contraindication to mri * history of brain surgery \<6 months * guardianship, tutelage or deprivation of liberty * pregnancy or breastfeeding * participation to other interventional clinical studies

Keywords: surgery - glioblastoma - fluorescein
methylated biomarkers predictive of endometrial cancer risk

Conditions: Endometrial Cancer

Summary: the goal of this observational study is to identify endometrial cancer risk predictive biomarkers and to optimise the methodology for their detection and quantification in non-invasive samples.


Eligibility criteria:
inclusion criteria: 1. women aged 45-70 years 2. attending st mary's hospital, manchester for an elective hysterectomy by any route for either the treatment of endometrial cancer or a benign gynaecological condition 3. able to consent to participation in the study exclusion criteria: 1. presence of malignancy asides from endometrial cancer 2. undergoing elective hysterectomy for suspected ovarian cancer

Keywords: risk prevention prediction
artificial pancreas in latin america

Conditions: Diabetes

Summary: the purpose of this study is to use closed-loop systems with the algorithms designed by the university of virginia and by the instituto tecnologico de buenos aires (itba)/ universidad nacional de la plata (unlp)/ universidad nacional de quilmes (unq) to determine the infusion of insulin in a prolonged period of time in patients with type 1 diabetes mellitus (t1dm).

aims: 1. to test university of virginia closed-loop algorithm with meal announcement for 36 hours at our facilities. 2. to test the ability of the closed-loopinstituto tecnologico de buenos aires (itba)/ universidad nacional de la plata (unlp)/ universidad nacional de quilmes (unq) algorithm without meal announcement to maintain glucose control for 2 periods of 12 hours in both cases, the adequate operation of the system will be considered verified if the system works properly at least 80% of the total connection time .

Eligibility criteria:
inclusion criteria: * patient have been diagnosed with t1dm at least two years ago and have been using an insulin pump and a cgm for at least 6 months prior to the trial first visit. * patient is \>18 and \<65 years. * patient has hba1c \> 6.5 % and \< 10%. * woman in premenopausal age agrees to use contraceptive methods. * woman in premenopausal age has negative b-hcg in the tests performed in the trial. * patient is trained in carbohydrates counting. * patient has signed informed consent and has the ability to understand the nature and intent of the study including the ability to comply with study procedures and is willing to keep scheduled visits. exclusion criteria: * patient has been hospitalized for diabetic ketoacidosis in the last 12 months. * patient has experienced severe hypoglycemia with loss of consciousness in the last 12 months. * patient has a history of coronary disease or cardiac failure. * patient with uncontrolled arterial hypertension. * patient with a condition that makes the researcher believe that it might increase the chance of hypoglycemia. * patient has symptoms compatible with an active infectious disease. * patient has cystic fibrosis. * pregnant women, or women with the intention of getting pregnant; women breastfeeding. * patient has been hospitalized for psychiatric treatment in the last 6 months. * patient with a diagnosis of an adrenal disease. * patient has abnormal laboratory values for liver function: transaminase \> 2x upper limit of normal. * patient has abnormal laboratory values for renal function: gfr \< 60 ml/min/1.73m2 * patient has active gastroparesis. * patient is under oncological treatment. * patient has taken acetaminophen 72 hours previous to the study.

Keywords: "artificial pancreas" "control system" "closed loop" diabetes "t1dm" "pump" algorithm cgm
efficacy and safety of acenocoumarol for treatment of nontumor portal vein thrombosis in cirrhosis of liver

Conditions: Portal Vein Thrombosis

Summary: after successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled. the baseline doppler parameter will be recorded and the patient will be randomized into either interventional (acenocoumarol) or placebo group along with first five days of subcutaneous low molecular weight heparin inj. enoxaparin in the interventional arm and placebo injection in the control arm. every 3 monthly the doppler screening for recanalization of portal vein thrombus will be done with monitoring of international normalized ratio (inr)with target inr 2-3. both the groups will receive the therapy for one year irrespective of the doppler findings in relation to portal vein thrombus re-canalization.then one year drug free monitoring will be done in both the groups as per the primary or secondary outcome. .


Eligibility criteria:
inclusion criteria: * a clinical, radiological or histologic diagnosis of cirrhosis * partial or total portal vein thrombus (evidence of chronic thrombus) * informed consent to participate in the study exclusion criteria: * acute thrombus in portal vein * hepatocellular carcinoma or any other malignancy, * hypercoagulable state other than the liver disease related * drugs- oral contraceptives, anticoagulation or anti-platelet drugs. * base line inr \>2 * child turcott pugh score\>11 * recent peptic ulcer disease * history of hemorrhagic stroke * pregnancy. * uncontrolled hypertension * age\>70 yrs * non responders to beta-blocker requiring endoscopic variceal ligation
efficacy and safety of mw031 in pmo subjects

Conditions: Osteoporosis, Postmenopausal

Summary: this study is a multicenter, randomized, double-blinded, placebo-controlled phase iii clinical study to evaluate the clinical efficacy and safety of mw031 in chinese postmenopausal osteoporotic subjects with increased bone fracture risk .


Eligibility criteria:
inclusion criteria: * bmd -4.0\<t-score ≤-2.5 at either the lumbar spine or total hip or femoral neck * all subjects must have at least one of following additional the risk factors:history of fracture, parental history of hip fracture, increased bone turnover rate at screening, low body weight, elderly (age≥65year)，current smoker * postmenopausal is defined as \>2 years postmenopausal, which can be \>2 years of spontaneous amenorrhea, or bilateral oophorectomy \>2 years after surgery. if bilateral oophorectomy status is unknown, use follicle-stimulating hormone (fsh) levels \> 40 miu/ml to confirm surgical postmenopausal status. exclusion criteria: * bone/metabolic disease * hyperparathyroidism or hypoparathyroidism * thyroid condition: hyperthyroidism or hypothyroidism * rheumatoid arthritis * malignant tumors * malabsorption syndrome * oral bisphosphonates
staying strong and healthy during androgen deprivation therapy (adt) for men

Conditions: Prostate Cancer

Summary: the purpose of this study is to learn if lifestyle changes and counseling along with standard medical care, compared to standard medical care alone, can prevent heart problems and diabetes in men who are receiving adt for prostate cancer treatment.

prostate cancer is a very treatable cancer but those treatments can have long-lasting effects. a kind of hormone therapy called androgen deprivation therapy (adt) is often used along with other treatments like radiation and has been shown to improve survival. however, adt can have negative effects especially on the heart and metabolism (the body's system for using and storing energy). participation in this study will last for up to 12 months. the study is looking at two different approaches to treating men who are undergoing adt: 1. staying strong \& healthy intervention + usual care 2. usual care all participants will have blood drawn and be asked questions about how they are feeling during their participation. the men in the staying strong \& healthy intervention group will also take part in a diet and exercise program and receive counseling from a member of the study team.

Eligibility criteria:
inclusion criteria: * diagnosed with prostate cancer * starting or have started adt (oral or injection) for prostate cancer treatment within the last 3 months * re-initiating adt after being on holiday for longer than their adt dosage (e.g. if the man's dosage is every six months and he has been off adt for more than six he is eligible); * able to speak and read in english or spanish * reachable consistently by telephone * able to travel to kumc exclusion criteria: * not diagnosed with prostate cancer * not receiving or planning to receive adt for prostate cancer treatment within the last three months * initiating adt for prostate cancer prior to the previous 3 months or are not on adt holiday * not able to speak and read in english or spanish * not reachable consistently by telephone * not able to travel to the study site for data collection

Keywords: androgen deprivation therapy adt
role of icco score in predicting outcome in icu patients

Conditions: Liver Cirrhosis

Summary: this study aims at calculating a specific score to cirrhotic patients admitted at icu (icco score) and use this score to predict mortality and outcome for admitted patients.

liver cirrhosis is the final stage of chronic liver disease. it is characterized by an irreversible replacement of liver parenchyma with fibrotic tissue and regenerative nodules. the major causes of cirrhosis include hepatitis b virus and hepatitis c virus infection, alcohol-associated liver disease (ald), and non-alcoholic fatty liver disease (nafld). the prognosis of cirrhotic patients admitted to the icu remains poor it was reported that the mortality rate of patients with cirrhosis admitted to an intensive care unit (icu) due to organ dysfunction ranges from 34% to 69% depending on the cause of admission, the presence of organ failure (of) and the severity of the underlying liver disease. several prognostic scoring systems have been used to assess patients with cirrhosis admitted to the icu, general icu mortality risk scores; such as the sequential organ failure assessment (sofa) score and the acute physiology and chronic health evaluation ii (apache ii) score, other liver specific scores such as model of end stage liver disease (meld) score. these scores can be calculated immediately upon admission to the icu (first 24 h) or during the first days of hospitalization, leading to an evolutionary assessment over this short period of time. intensive care cirrhotic outcome (icco) score is a new score that was introduced to predict mortality and icu outcome in cirrhotic patients admitted to the icu. with limited studies that test the validity of the score and compare it with the other well-known icu scores. in clinical practice, it remains controversial to determine which score is better at predicting overall mortality, this is due to that each score is calculated according to its own criteria, and only data obtained within the first 24 hours of the first icu admittance is used. in this study investigators will test the validity of icco score and compare it with other different icu scores to find out the most useful score in early prediction of icu outcome for cirrhotic patients.

Eligibility criteria:
inclusion criteria: * adult patients (age ≥18 years) with cirrhosis admitted to the icu. * confirmed diagnosis of cirrhosis based on clinical, radiological, and/or histological criteria. * need for intensive care management due to acute illness or complications related to cirrhosis. exclusion criteria: * patients without a confirmed diagnosis of cirrhosis. * patients with acute liver failure not meeting criteria for cirrhosis. * patients with incomplete data for calculating icco. * patients transferred from another icu. * patients who refuse participation in the study.
a prospective munti-center study on vanguard™ ps total knee replacement system

Conditions: Osteoarthritis; Rheumatoid Arthritis; Traumatic Arthritis; Posttraumatic Deformity

Summary: the primary objectives of this pilot clinical study include: * evaluate clinical outcomes and quality of life on patients who received vanguard ps total knee in korean population * evaluate safety of vanguard ps total knee in korean population

this study is a prospective, single cohort, multi-center study of vanguard ps system and will be conducted in korea with 2 institutions. the study will be conducted over a period of 10 years. patients will be followed at immediate post-op, 6 weeks, 6 months and 1 year, 3 years. total of 2 sites will be involved in this study. 50 cases on each sites and total of 100 subjects will be enrolled in the study. primary end-point will be kss at 1 year post op and secondary end-points are survivorship of the product, kss, eq5d, high-flexion knee score, radiographic assessment, and any kind of complication including lost to follow up.

Eligibility criteria:
inclusion criteria: * painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis, where one or more compartments are involved. * correction of varus, valgus, or posttraumatic deformity. * correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure * need to obtain pain relief and improve function * ability and willingness of the patient to follow instructions, including control of weight and activity level * a good nutritional state of the patient, and * the patient must have reached full skeletal maturity (at least 18 years old). exclusion criteria: * infection * sepsis * osteomyelitis * uncooperative patient or patient with neurologic disorders who are incapable of following directions * osteoporosis * metabolic disorders which may impair bone formation * osteomalacia * distant foci of infections which may spread to the implant site * rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram * vascular insufficiency, muscular atrophy, neuromuscular disease * incomplete or deficient soft tissue surrounding the knee
the effect of whey protein on short-term food intake and post-meal blood glucose response in young men

Conditions: Diabetes Prevention; Obesity Prevention

Summary: the objective of this study was to describe relationships among whey protein when consumed before a meal on food intake and pre- and post-meal satiety, blood glucose in healthy young adults.

a randomized, cross-over design study was conducted. whey protein preloads (10-40 g) were provided in 300 ml water. at 30 min following consumption, subjects were fed an ad libitum pizza meal. satiety, and blood glucose were measured at baseline and selected intervals pre- (0, 15 and 30 min) and post-meal (50, 65, 80 and 95 min).

Eligibility criteria:
inclusion criteria: * healthy * normal weight ( 18-24.9 kg/m²) * young aged 20-27 year old exclusion criteria: * breakfast skippers * smokers * dieters * individuals with diabetes (fasting bg ≥ 7.0 mmol/l) or other metabolic diseases

Keywords: whey protein subjective appetite shor-term food intake blood glucose
preoxygenation with optiflow™ in morbidly obese patients is superior to face mask

Conditions: Obesity, Morbid

Summary: optiflow™ may provide an opportunity to prolong apnea time in the morbidly obese patient population. this study will examine whether optiflow can do this, and compare the pre-oxygenation with optiflow to the pre-oxygenation achieved with face mask.

the use of high flow nasal cannula (hfnc) originated in neonatal care, and has become widespread in its application for patients that are high risk for hypoxemia, both in critical care and emergency settings. therefore, high flow nasal oxygenation continues to be studied in airway management for preoxygenation, as well as maintenance of oxygenation in airway procedures. optiflow™, a humidified high flow nasal cannula, has already been shown to be useful in preventing desaturation during intubation in icu patients versus the non-rebreathing mask, in addition to, prolonging safe apnea time in patients with potential difficult airways. additionally, preoxygenation with hfnc prior to intubation of patients in hypoxemic respiratory failure has also been shown to decrease desaturation during apnea compared to preoxygenation with traditional bag valve mask. the morbidly obese patient presents a separate group of challenges to the anesthesiologist in regards to mask ventilation and intubation. obesity (along with other factors) has been shown to contribute to difficulty with mask ventilation. obese patients have altered respiratory physiology, including decreased functional residual capacity, increased oxygen consumption and lower tidal volumes, as compared to the non-obese patient. these factors contribute to obese patients potentially having a shorter apnea time before desaturating during induction of general anesthesia, as compared to the non-obese patient. weight is inversely correlated with safe apnea time. optiflow™ may provide an opportunity to prolong apnea time in the morbidly obese patient population. if demonstrated to be efficacious as a method for preoxygenation and prolongation of apneic time, this could provide a safer environment for intubation in this particular patient population.

Eligibility criteria:
inclusion criteria: * adult patients (≥ 18 years old) undergoing elective surgery requiring general anesthesia * bmi \> 40 kg/m2 * american society of anesthesiology (asa) physical status ii-iii exclusion criteria: * chronic hypoxemia (spo2 \<94% on room air or on home oxygen) * acute respiratory failure * coronary artery disease and/or congestive heart failure * moderate-severe pulmonary hypertension and/or rv dysfunction * full stomach (recently eaten) * pregnancy * chronic pulmonary disease (specifically copd or interstitial disease, not asthma) * respiratory tract pathology * facial abnormality * american society of anesthesiology (asa) physical status iv-v
neuropsychologic and immunological evaluation in treatment of thyroid diseases. is selenium efficient?

Conditions: QoL Before and After 9 Month of Medical Treatment of Graves´Thyrotoxicosis; Potential Effect of Selenium

Summary: graves thyrotoxicosis is a common autoimmune disease. patients suffer at diagnosis from weight loss, increased heart rate and stress intolerance. some patients have difficulties in regaining quality of life. diagnosis is found through elevated thyroid hormones thyroxin, suppressed tsh (thyroid stimulating hormone) from the pituitary and elevated stimulatory antibodies, trab (thyrotropin receptor antibody) to the thyroid. selenium is sparse in western europe. this compound has important function in thyroid hormone metabolism and on the immune system. it is not known whether addition of selenium affects the well being of patients with graves´thyrotoxicosis. the subject of this study is to investigate this

in the county of södermanland we include 44 patients with graves´thyrotoxicosis. they are treated with methimazole and thyroxin, and randomised to selenium or placebo. neuropsychological investigation is performed, before medical treatment is commenced and repeated after 9 month. serum concentration of thyroid hormon levels, autoantibodies and selenium are followed.

Eligibility criteria:
inclusion criteria: * new diagnose of autoimmune thyrotoxicosis * biochemically proven with increased thyroxin * low tsh and elevated trab/or positive scintigraphy. * age 18 - 55. willing to participate - exclusion criteria: * no previous head trauma, * no difficulties with swedish language, * no medication which could affective neuropsychological testing, * no planned or ongoing pregnancies. * normal intellectual capacity. * no severe ophthalmopathy, or other severe disease

Keywords: selenium neuropsychological testing autoantibodies
characterization of rectal cancer hypoxia using po2 histography and immunohistochemistry for hypoxia-related proteins

Conditions: Rectal Cancer

Summary: the purpose of this study is to see if the cells in rectal cancer are oxygen-starved, or hypoxic. we know that as cancers grow bigger, parts of them are cut off from the oxygen supply and they become hypoxic, basically, lacking oxygen. research has shown that cells that are oxygen-starved respond differently to treatment such as chemotherapy and radiation when compared to cells that are oxygen rich.


Eligibility criteria:
inclusion criteria: * biopsy proven adenocarcinoma of the rectum. if a biopsy was taken at an outside hospital, the slides and diagnosis will be reviewed and confirmed by a pathologist at mskcc. * mid to distal rectal tumors not requiring pre-op radiation or chemotherapy * age ≥ 18 * age \< 90 * karnofsky performance status ≥ 60 * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * current pregnancy * uncontrolled intercurrent illness that would limit compliance with study requirements.

Keywords: direct po2 measurements 10-121